GlobeNewswire Inc | Jun 3, 2021 04:05PM EDT

June 03, 2021

SOUTH SAN FRANCISCO, Calif., June 03, 2021 (GLOBE NEWSWIRE) -- Alector, Inc.(Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that Shehnaaz Suliman, M.D., MBA, M.Phil., president and chief operating officer of Alector, will participate in fireside chats at the following upcoming virtual investor conferences:

-- The Goldman Sachs 42nd Annual Global Healthcare Conference Thursday, June 10, 2021, at 4:40 p.m. ET -- The BofA Securities 2021 Napa Biopharma Virtual Conference Monday, June 14, 2021, at 5:30 p.m. ET

Live webcasts of both presentations will be available on the Events & Presentations page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 30 days following the presentation dates.

AboutAlector

Alectoris a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Companyis developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brains immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies.Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.The Companys immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimers disease. This scientific approach is also the basis for the Companys immuno-oncology programs.Alectoris headquartered inSouthSan Francisco,California. For additional information, please visitwww.alector.com.

Contacts

1ABDan Budwick973-271-6085dan@1abmedia.com

or

Investors:Alector, Inc.ir@alector.com